Sublimity’s goal is to identify and create meaningful new therapies for unmet clinical needs in gastrointestinal and immunological diseases. Our priority focus is on our lead program: ST-0529, for treatment of moderate to severe ulcerative colitis.
Sublimity’s proprietary SmPill® technology is a versatile delivery system for solubilizing active therapeutic agents that are otherwise poorly soluble due to their molecular properties.
ST-0529 is an oral formulation of cyclosporine that is being developed for the treatment of moderate to severe ulcerative colitis. ST-0529 has been designed using Sublimity’s proprietary SmPill® delivery system.
Sublimity Therapeutics is a clinical-stage biotechnology company dedicated to identifying and developing meaningful new therapies for unmet clinical needs in gastrointestinal and immunological diseases. Led by a team of industry innovators and leveraging our Single-Multiple Pill (SmPill®) technology, we are advancing a diverse pipeline of oral small molecules that have the potential to make important contributions to human health. Our lead asset ST-0529 is currently being evaluated in the AURORA (CYC-202) Study, a Phase 2b clinical trial for moderate to severe Ulcerative Colitis.
Sublimity is a proud sponsor of the Crohn’s & Colitis Foundation.
More information on the AURORA study, including participating research sites can be found here in the Crohn’s & Colitis Foundation’s Featured Research section
Ulcerative Colitis: the Need for New Treatments
The SmPill® drug delivery platform is a ground-breaking technical innovation that may lead to the development new therapies like ST-0529 to treat diseases of the gastrointestinal tract where unmet clinical needs exist.
SmPill® is a versatile delivery system for solubilizing active therapeutic agents that are otherwise poorly soluble due to their molecular properties.
Sublimity is advancing a diverse pipeline of oral small molecules and peptides that have the potential to make important contributions to human health.
It is estimated that ulcerative colitis affects more than 1.7 million patients in North America, Europe and other developed countries. The moderate to severe patient segment represents the fastest growing patient population and also accounts for more than 66 percent of all patients with the disease.read more